GS-9822
GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1].
Product Specifications
CAS Number
2219362-41-9
UNSPSC
12352005
Target
HIV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/gs-9822.html
Solubility
10 mM in DMSO
Smiles
CC(C)(C)O[C@@H](C1=C(C)C=C(N=C(C2=CC=C3C(C(C4CCN(C5COC5)CC4)=NN3C)=C2)S6)C6=C1C7=CC=C(Cl)C=C7)C(O)=O
Molecular Formula
C36H39ClN4O4S
Molecular Weight
659.24
References & Citations
[1]Bruggemans A, et al. GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2023 May 1;65 (5) :e02328-20.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Bis[2-(2-mercaptobenzoyl)hydrazide] 2,2'-Dithiobis-benzoic Acid](https://cdn.genprice.uk/products/572/3647514186250/imageurl/trc-b481830-50mg.webp)
TRC-B481830-50MG 50 mg
Bis[2-(2-mercaptobenzoyl)hydrazide] 2,2'-Dithiobis-benzoic Acid
Sign In for Pricing
View Details 
